Trials / Completed
CompletedNCT00868959
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
A 24-Week, Flexible-Dose, Open-Label Extension Study of Lurasidone for the Treatment of Bipolar I Depression
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 817 (actual)
- Sponsor
- Sumitomo Pharma America, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe for the treatment of patients with bipolar I depression
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lurasidone | Lurasidone 20-120 mg/d Flexibly Dosed - 24 weeks |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2013-02-01
- Completion
- 2013-02-01
- First posted
- 2009-03-25
- Last updated
- 2016-04-14
- Results posted
- 2014-04-01
Locations
151 sites across 15 countries: United States, Canada, Colombia, Czechia, France, India, Japan, Lithuania, Peru, Poland, Romania, Russia, Slovakia, South Africa, Ukraine
Source: ClinicalTrials.gov record NCT00868959. Inclusion in this directory is not an endorsement.